Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

医学 腹水 肝硬化 内科学 危险系数 临床终点 随机对照试验 意向治疗分析 白蛋白 胃肠病学 临床试验 置信区间 外科
作者
Paolo Caraceni,Oliviero Riggio,Paolo Angeli,Carlo Alessandria,Sergio Neri,Francesco Giuseppe Foschi,Fabio Levantesi,Aldo Airoldi,Sergio Boccia,Gianluca Svegliati‐Baroni,S. Fagiuoli,Roberto Giulio Romanelli,Raffaele Cozzolongo,V. Di Marco,Vincenzo Sangiovanni,Filomena Morisco,Pierluigi Toniutto,Annalisa Tortora,Rosanna De Marco,M. Angélico
出处
期刊:The Lancet [Elsevier BV]
卷期号:391 (10138): 2417-2429 被引量:431
标识
DOI:10.1016/s0140-6736(18)30840-7
摘要

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding Italian Medicine Agency.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国应助不安的秋白采纳,获得10
2秒前
忧伤的步美完成签到,获得积分10
7秒前
小西完成签到 ,获得积分10
8秒前
郝老头完成签到,获得积分10
9秒前
13313完成签到,获得积分10
10秒前
su完成签到 ,获得积分10
11秒前
14秒前
19秒前
量子星尘发布了新的文献求助10
19秒前
slayers完成签到 ,获得积分10
19秒前
21秒前
知犯何逆完成签到,获得积分10
23秒前
Krsky完成签到,获得积分10
25秒前
ding应助不安的秋白采纳,获得10
26秒前
27秒前
29秒前
HHHAN发布了新的文献求助10
33秒前
威武的沂完成签到,获得积分10
38秒前
40秒前
41秒前
43秒前
笨笨青筠完成签到 ,获得积分10
46秒前
mengmenglv完成签到 ,获得积分0
46秒前
Tonald Yang完成签到 ,获得积分20
49秒前
50秒前
落后的怀梦完成签到 ,获得积分10
51秒前
陈坤完成签到,获得积分10
53秒前
量子星尘发布了新的文献求助10
55秒前
斯文败类应助zgx采纳,获得10
56秒前
默默完成签到 ,获得积分10
56秒前
KY Mr.WANG完成签到,获得积分10
56秒前
1分钟前
guoxingliu完成签到,获得积分10
1分钟前
1分钟前
阳佟水蓉完成签到,获得积分10
1分钟前
gdgd完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
叮叮当当完成签到,获得积分10
1分钟前
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022